Hoedemaekers R
School of Medical Sciences, KUN Nijmegen, The Netherlands.
J Med Ethics. 2000 Aug;26(4):282-6. doi: 10.1136/jme.26.4.282.
In Europe a process of harmonisation of standards and regulations on genetic testing has started. Public discussion and consultation are recommended, but it is not clear in every European country how the decision making process as regards the further introduction of genetic testing services should be formed. In this paper the usefulness and importance of an overseeing body for genetic screening and testing is founded on four lines of reasoning: (1) analysis of the role of value judgments in the use of the concept of (genetic) abnormality; (2) a balancing of potential benefits for all parties involved; (3) a balancing of potential disadvantages, and (4) the greater availability of commercial genetic tests in the future. It is further argued that such an overseeing body has advantages for all the interested parties.
在欧洲，基因检测标准和法规的协调进程已经启动。建议进行公众讨论和咨询，但在每个欧洲国家，关于进一步引入基因检测服务的决策过程应如何形成尚不清楚。在本文中，基于四条推理思路确立了基因筛查和检测监督机构的有用性和重要性：（1）分析价值判断在（基因）异常概念使用中的作用；（2）平衡所有相关方的潜在利益；（3）平衡潜在弊端；（4）未来商业基因检测的更多可得性。进一步论证的是，这样一个监督机构对所有利益相关方都有好处。
